Deep Bio: Demonstrated globally-recognized standards in safety and quality management as a medical software manufacturer SEOUL, SOUTH KOREA (PRWEB) AUGUST 16, 2022 Deep Bio, a pioneer in medical AI for pathologic cancer diagnostics, announced...

Seoul, South Korea, and Albuquerque, NM – August 9, 2022 – Deep Bio, a company concentrating on SaMD (Software as a Medical Device) for digital pathology, offering clinically validated, AI-based DeepDx® algorithms, and Indica Labs, a...

Deep Bio: This designation marks the Korean government’s recognition of innovation for DeepDx®-Prostate Pro SEOUL, SOUTH KOREA (PRWEB) JULY 25, 2022 Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics software,...

Deep Bio Presents Research Results of AI-based Cancer Diagnosis and Prognosis at the AACR Annual Meeting 2022 Five abstracts in prostate and breast cancers, Deep Bio’s main research areas, are presented during the online sessions. SEOUL,...

Join Deep Bio at AACR 2022! At this year’s AACR, Deep Bio will present both on-site and virtually! Visit us at booth #1461 to share your thoughts on the role of digital pathology and AI in cancer research. Also, don’t forget to see the...

Join Deep Bio at USCAP 2022 We are excited to finally meet you in person at USCAP 2022! Explore how Deep Bio’s AI solutions have shaped digital pathology. Learn about the new insights from our studies. Deep Bio will be exhibiting...